Lung Adenocarcinoma Treatment Market, By Drug Class (EGFR Inhibitors, ALK Inhibitors, PD-1/PD-L1 Inhibitors and VEGF Inhibitors), By Therapy Type, By Stage of Treatment, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Lung Adenocarcinoma Treatment Market size was valued at USD 5,512.09 Million in 2023, expanding at a CAGR of 10.70% from 2024 to 2032.
The Lung Adenocarcinoma Treatment Market encompasses therapies specifically aimed at treating lung adenocarcinoma, a common subtype of non-small cell lung cancer. With rising global incidences, attributed to increased smoking rates and environmental factors, the market is witnessing significant growth. According to the American Cancer Society, approximately 236,000 new cases of lung cancer are expected in the U.S. in 2023, with adenocarcinoma accounting for nearly 40% of those cases. Advances in targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors, are enhancing treatment options, while immunotherapy is gaining traction for its effectiveness in advanced stages. However, challenges such as high treatment costs and adverse side effects may hinder market expansion. Nevertheless, ongoing research and development initiatives aimed at improving existing therapies and the emergence of personalized medicine present substantial opportunities for market players, fostering innovations that could transform patient outcomes in lung adenocarcinoma treatment.
Lung Adenocarcinoma Treatment Market- Market Dynamics
Rising Smoking Rates Fuel Growth in the Lung Adenocarcinoma Treatment Market
The escalating rates of smoking worldwide significantly contribute to the growth of the Lung Adenocarcinoma Treatment Market, as smoking is a primary risk factor for lung cancer. The World Health Organization (WHO) estimates that over 1.3 billion people are currently smokers, with tobacco use accounting for nearly 22% of cancer-related deaths globally. In the United States, the Centers for Disease Control and Prevention (CDC) reports that lung cancer is the leading cause of cancer mortality, with smoking responsible for approximately 85% of cases. As public awareness campaigns increase and smoking cessation programs are implemented, the demand for effective treatments is anticipated to rise. Pharmaceutical companies are responding to this trend by investing in innovative therapies, including targeted treatments and immunotherapies, to address the growing patient population. Additionally, initiatives from organizations like the American Lung Association aim to reduce smoking prevalence and improve early diagnosis, further driving the need for advanced treatment options in the lung adenocarcinoma sector.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc. (Roche)
Gilead Sciences, Inc.
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Others
GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
EGFR Inhibitors
ALK Inhibitors
PD-1/PD-L1 Inhibitors
VEGF Inhibitors
GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
Chemotherapy
Targeted Therapy
Immunotherapy
Combination Therapy
GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY STAGE OF TREATMENT- MARKET ANALYSIS, 2019 - 2032
Early-Stage Adenocarcinoma
Advanced or Metastatic Adenocarcinoma
GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
Hospitals
Oncology Clinics
Research Institutions
GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
o The U.S.
o Canada
Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Russia
o Netherlands
o Sweden
o Poland
o Rest of Europe
Asia Pacific
o India
o China
o South Korea
o Japan
o Australia
o Thailand
o Indonesia
o Philippines
o Rest of APAC
Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
The Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Lung Adenocarcinoma Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Lung Adenocarcinoma Treatment Market Snippet by Drug Class
2.1.2. Lung Adenocarcinoma Treatment Market Snippet by Therapy Type
2.1.3. Lung Adenocarcinoma Treatment Market Snippet by Stage of Treatment
2.1.4. Lung Adenocarcinoma Treatment Market Snippet by End-User
2.1.5. Lung Adenocarcinoma Treatment Market Snippet by Country
2.1.6. Lung Adenocarcinoma Treatment Market Snippet by Region
2.2. Competitive Insights
3. Lung Adenocarcinoma Treatment Key Market Trends
3.1. Lung Adenocarcinoma Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Lung Adenocarcinoma Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Lung Adenocarcinoma Treatment Market Opportunities
3.4. Lung Adenocarcinoma Treatment Market Future Trends
4. Lung Adenocarcinoma Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Lung Adenocarcinoma Treatment Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Lung Adenocarcinoma Treatment Market Landscape
6.1. Lung Adenocarcinoma Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Lung Adenocarcinoma Treatment Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
7.1.2. EGFR Inhibitors
7.1.3. ALK Inhibitors
7.1.4. PD-1/PD-L1 Inhibitors
7.1.5. VEGF Inhibitors
8. Lung Adenocarcinoma Treatment Market – By Therapy Type
8.1. Overview
8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
8.1.2. Chemotherapy
8.1.3. Targeted Therapy
8.1.4. Immunotherapy
8.1.5. Combination Therapy
9. Lung Adenocarcinoma Treatment Market – By Stage of Treatment
9.1. Overview
9.1.1. Segment Share Analysis, By Stage of Treatment, 2023 & 2032 (%)
9.1.2. Early-Stage Adenocarcinoma
9.1.3. Advanced or Metastatic Adenocarcinoma
10. Lung Adenocarcinoma Treatment Market – By End-User
10.1. Overview
10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
10.1.2. Hospitals
10.1.3. Oncology Clinics
10.1.4. Research Institutions
11. Lung Adenocarcinoma Treatment Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Lung Adenocarcinoma Treatment Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Lung Adenocarcinoma Treatment Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.9. Italy
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.9.5. Italy Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.10. United Kingdom
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.10.5. United Kingdom Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.11. France
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.11.5. France Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.12. Russia
11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.12.4. Russia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.13. Netherlands
11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.13.4. Netherlands Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.15. Poland
11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.15.4. Poland Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.16. Rest of Europe
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.16.5. Rest of the Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Lung Adenocarcinoma Treatment Key Manufacturers in Asia Pacific
11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.6. Asia Pacific Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.8. India
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.8.5. India Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.9. China
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.9.5. China Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.13. Thailand
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.13.5. Thailand Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.14. Indonesia
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.14.5. Indonesia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
11.5.1. Overview
11.5.2. Lung Adenocarcinoma Treatment Key Manufacturers in Latin America
11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.6. Latin America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
11.6.1. Overview
11.6.2. Lung Adenocarcinoma Treatment Key Manufacturers in Middle East and Africa
11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.6. Middle East and Africa Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Lung Adenocarcinoma Treatment Industry
12.1. Competitive Dashboard
12.2. Company Profiles
12.2.1. Amgen Inc.
12.2.2. Astellas Pharma Inc.
12.2.3. AstraZeneca PLC
12.2.4. Bayer AG
12.2.5. Boehringer Ingelheim GmbH
12.2.6. Bristol-Myers Squibb Company
12.2.7. Eli Lilly and Company
12.2.8. Genentech, Inc. (Roche)
12.2.9. Gilead Sciences, Inc.
12.2.10. GlaxoSmithKline plc
12.2.11. Janssen Pharmaceuticals, Inc.
12.2.12. Merck & Co., Inc.
12.2.13. Novartis AG
12.2.14. Pfizer Inc.
12.2.15. Sanofi S.A.
12.2.16. Takeda Pharmaceutical Company Limited
12.2.17. Others
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
